Tevogen highlights potential role of TVGN 489 on impact of Long COVID

Tevogen (TVGN) highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published in Sci Trans Med, Clin Microbial Infect and The Lancet Infectious Diseases report the detection of residual SARS-CoV-2 proteins and RNA for months to years after acute infection in individuals. This persistence suggests the presence of a viral reservoir which results in chronic immune inflammation and dysfunction underlying Long COVID symptoms. These findings open new avenues for therapeutic approaches aimed at eliminating the residual virus and restoring immune and physiological homeostasis.